The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation

---

Copy For Citation

van Zonneveld M., Flink H., Verhey E., Senturk H., Zeuzem S., Akarca U., ...More

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, vol.21, no.9, pp.1163-1171, 2005 (SCI-Expanded)

• Publication Type: Article / Article
• Volume: 21 Issue: 9
• Publication Date: 2005
• Doi Number: 10.1111/j.1365-2036.2005.02453.x
• Journal Name: ALIMENTARY PHARMACOLOGY & THERAPEUTICS
• Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
• Page Numbers: pp.1163-1171
• Bezmialem Vakıf University Affiliated: Yes

Abstract

Background: Treatment with interferon-alpha has been shown to be effective in one-third of hepatitis B e antigen-positive chronic hepatitis B patients, but is clinically associated with relevant adverse events.